“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

Tevogen Bio files patent for T cell vaccine targeting entire viral genome, enhancing immune response against mutations and viral infections. Tevogen Bio, a clinical-stage immunotherapy biotech company ...

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing a clinical-stage allogeneic cell therapy. The layoffs are expected to be ...

When a cell divides, it performs a feat of microscopic choreography—duplicating its DNA and depositing it into two new cells.

Multicellularity is one of the most profound phenomena in biology, and relies on the ability of a single cell to reorganize ...

Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...

When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie. The company, Tolerance Bio, focuses on preserving the body’s ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

A new type of tissue model that more accurately mimics the architecture of the liver could help develop drugs to treat MASLD.